Metotreksat Sandoz 2,5 mg tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

metotreksat sandoz 2,5 mg tablete

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - dinatrijev metotreksat - tableta - 2,5 mg - urbroj: jedna tableta sadrži 2,5 mg metotreksata, u obliku dinatrijevog metotreksata

APIDRA 100 jedinica/1 mL rastvor za injekciju u napunjenom penu Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

apidra 100 jedinica/1 ml rastvor za injekciju u napunjenom penu

sanofi d.o.o. - inzulin glulisin - rastvor za injekciju u napunjenom penu - 100 jedinica/1 ml - 3 ml rastvora za injekciju u napunjenom penu sadrži: 300 jedinica (odgovara 3,49 mg/ml) insulin glulisin

APIDRA SOLOSTAR 100 jedinica/1 mL rastvor za injekciju u napunjenom penu Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

apidra solostar 100 jedinica/1 ml rastvor za injekciju u napunjenom penu

amicus pharma d.o.o. - inzulin glulisin - rastvor za injekciju u napunjenom penu - 100 jedinica/1 ml - 3 ml rastvora za injekciju u napunjenom penu sadrži: 300 jedinica (odgovara 3,49 mg/ml) insulina glulisina

Imatinib Actavis Europska Unija - hrvatski - EMA (European Medicines Agency)

imatinib actavis

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. učinak иматиниба na ishod transplantacije koštane srži nije određena. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. iskustvo s иматинибом u bolesnika s mds/rafinerija u svezi s pdgfr генных permutacija-vrlo ograničen. nema kontroliranih istraživanja pokazuju kliničku korist ili povećanje preživljavanja za te bolesti.

Imatinib Sandoz 100 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

imatinib sandoz 100 mg filmom obložene tablete

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - imatinibmesilat - filmom obložena tableta - 100 mg - urbroj: svaka filmom obložena tableta sadrži 100 mg imatiniba (u obliku mesilata)